Commercial failure of iDose TR
The product is newly commercialized and needs physician adoption, reimbursement, and manufacturing scale.
- Scope
- Core growth product
- Materiality
- high
GLAUKOS Corp
Glaukos Corp develops and commercializes ophthalmic therapies and devices focused on glaucoma, corneal disorders, and emerging anterior/posterior segment treatments. The company sells products such as iStent, iDose TR, Photrexa, and Epioxa through direct sales in the U.S. and a mix of subsidiaries and distributors internationally.
−31,8 %
55,7 %
−37,0 %
+32,3 %
4.69
4.06
| % | |
|---|---|
| Glaucoma surgical devices | 60% Micro-invasive glaucoma surgery products used by surgeons to reduce intraocular pressure. |
| Procedural pharmaceuticals | 23% Drug-device therapies such as iDose TR used in ophthalmic procedures. |
| Corneal cross-linking therapies | 15% Photrexa and Epioxa products used in keratoconus and corneal disorder treatment. |
| Pipeline and other ophthalmology programs | 2% Clinical and pre-clinical programs targeting broader ophthalmic indications. |
Glaukos sells primarily to ophthalmic surgeons and other eye care professionals, with end-user demand concentrated in...
- Ambulatory surgery centersprimary
Buy iStent, iDose TR, and corneal products for outpatient ophthalmic procedures and efficiency.
- Hospitalsprimary
Purchase ophthalmic devices and therapies for surgical and specialty eye care programs.
- Physician private practicesprimary
Use Glaukos products for glaucoma and corneal treatment in office-based care settings.
- International distributorssecondary
Buy and resell products in countries where Glaukos lacks direct commercial operations.
- Ophthalmic surgeons and eye care professionalsprimary
Influence product adoption through procedure preference, training, and clinical acceptance.
Glaukos generates most of its revenue in the United States, with the remainder coming from international markets...
- •U.S. accounted for 74% of net sales in 2025
- •International markets accounted for 26% of net sales in 2025
- •U.S. sales are mainly through a direct sales organization
- •International sales use subsidiaries and distributors in selected countries
- •Huntsville, Alabama is a key planned R&D and manufacturing expansion site
Glaukos is expanding beyond its core glaucoma franchise by commercializing iDose TR and launching Epioxa while...
01
Commercialize iDose TR successfullyshort-term
It is a newly commercialized product and a key growth driver, but adoption and reimbursement must scale.
02
Launch Epioxa in early 2026short-term
FDA approval expands the corneal franchise and diversifies revenue beyond glaucoma.
03
Expand manufacturing and R&D footprintmedium-term
Capacity is needed to meet demand and support a broader product portfolio.
04
Advance pipeline programsmedium-term
Pipeline success could extend the company into larger ophthalmology markets.
Glaukos depends heavily on the commercial success of a small number of products, especially iDose TR and Epioxa, so...
Commercial failure of Epioxa
The product is newly approved and must establish clinical acceptance and payer support.
- Scope
- New corneal franchise
- Materiality
- high
Competitive pressure in ophthalmology
Large medtech and pharma companies compete in glaucoma, corneal disorders, and future pipeline indications.
- Scope
- Glaucoma, corneal, anterior/posterior segment
- Materiality
- high
Manufacturing capacity constraints
Growth requires expansion of production and facility build-out, which can delay supply or raise costs.
- Scope
- U.S. and global supply chain
- Materiality
- high
International commercial execution
Some markets rely on distributors rather than direct operations, which can limit control and growth.
- Scope
- 26% of 2025 sales
- Materiality
- medium
Revenue recognition and variable consideration
Can shift reported revenue and margins period to period
Inventory reserves
Can materially affect gross margin when demand or product mix changes
Lease accounting
Affects balance sheet liabilities and cash flow presentation
Capital expenditures and facility build-out
Raises depreciation, capitalized asset balances, and future fixed-cost burden
: 28.4.2026